Direct-acting antivirals now ready for prime time

Studies show encouraging data in a wide range of HCV patient populations

2013-04-24

(Press-News.org) Amsterdam, The Netherlands, Wednesday 24 April 2013: New data from a number of clinical trials presented for the first time at the International Liver Congress™ 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

The following covers key results from the much anticipated Phase III trials conducted among HCV patients with a range of genotypes (GT 1 to 6) on DAA treatment.

POSITRON A study of interferon (IFN)-ineligible, IFN-intolerant, or IFN-unwilling cirrhotic and non-cirrhotic GT 2 and 3 HCV-infected patients treated with a combination of sofosbuvir and ribavirin for 12 weeks achieved a high SVR12 rate without evidence of resistance. In the POSITRON Phase III trial, the SVR12 rate of 78% for sofosbuvir and ribavirin (161/207) was superior to placebo (0%, p< 0.001) and all 278 patients became HCV RNA negative on treatment. In terms of adverse events only 2% of patients discontinued treatment in the sofosbuvir + ribavirin group due to adverse events vs. 4% in the placebo group.

NEUTRINO Treatment with a combination of sofosbuvir, peginterferon alfa-2a and ribavirin for 12 weeks achieved 90% SVR12 in treatment naïve genotype 1, 4, 5, or 6 HCV-infected patients with no viral resistance detected in failures, according to the results of the Phase III NEUTRINO study. The regimen was well tolerated and is a short, simple and effective treatment option for patients with these genotypes. A total of 327 patients (292 genotype 1, 28 genotype 4, 7 genotype 5/6) were enrolled and received the study drug.

EASL Secretary General Prof. Mark Thursz commented on the studies: "Unlike the US, in Europe and Asia genotype 3 is quite common. As such for European audiences the interferon-free results in genotype 3 are not as impressive as expected; however the side effect profile and lack of viral resistance means that longer treatment durations will be evaluated in the near future. In the meantime, we feel it's not time to bury pegylated interferon just yet."

"Many patients can tolerate 12 weeks of an interferon based regime particularly when it produces SVR rates of more than 90%; so clearly the results of the NEUTRINO study will be welcomed by clinicians and patients" added Prof. Thursz.

STARTVerso™1 Faldaprevir, an oral once-daily protease inhibitor, in combination with peginterferon alfa-2a and ribavirin (PegIFN/RBV) significantly increased SVR12 rates in treatment-naïve HCV GT-1 patients in Europe and Japan compared with PegIFN/RBV alone and was well tolerated. In total 652 patients were treated and 88% of patients treated with faldaprevir were eligible to stop all treatment at week 24.

QUEST-1 and -2 QUEST-1: Simeprevir, an oral once-daily protease inhibitor, in combination with peginterferon alfa-2a and ribavirin (PegIFN/RBV) achieved SVR12 rates of 80% compared to placebo, 50% (p END

ELSE PRESS RELEASES FROM THIS DATE:

Battery and memory device in 1

2013-04-24

Resistive memory cells (ReRAM) are regarded as a promising solution for future generations of computer memories. They will dramatically reduce the energy consumption of modern IT systems while significantly increasing their performance. Unlike the building blocks of conventional hard disk drives and memories, these novel memory cells are not purely passive components but must be regarded as tiny batteries. This has been demonstrated by researchers of Jülich Aachen Research Alliance (JARA), whose findings have now been published in the prestigious journal Nature Communications. ...

New research findings on the brain's guardian cells

2013-04-24

Researcher Johan Jakobsson and his colleagues have now published their results in Nature Communications. "At present, researchers know very little about exactly how microglia work. At the same time, there is a lot of curiosity and high hopes among brain researchers that greater understanding of microglia could lead to entirely new drug development strategies for various brain diseases", says Johan Jakobsson, research group leader at the Division of Molecular Neurogenetics at Lund University. What the researchers have now succeeded in identifying is a deviation in the ...

Huddersfield scientist helps to reveal a link in the evolutionary chain

2013-04-24

An international team of scientists, including Dr Paul Brotherton from the University of Huddersfield, reveal that events after the initial migration of farmers into Europe had a major impact on the modern gene pool. The paper, published in Nature Communications, investigates a major component of the maternal population history of modern Europeans by focusing on haplogroup H mitochondrial genomes from ancient human remains. This genetic data is then compared with cultural changes taking place between the Early Neolithic (~5450 BC) and Bronze Age (~2200 BC) in Central Europe. ...

Microscopic dust particles found in underground railways may pose health risk

2013-04-24

New research from the University of Southampton has found that working or travelling on an underground railway for a sustained period of time could have health implications. Previously published work suggests that working in environments such as steel mills or welding plants, which are rich in airborne metals, like iron, copper and nickel, can have damaging effects on health. However, little research has been done on the effects of working in an underground railway environment – a similarly metal-rich environment – and results of studies that have been conducted are often ...

Video reveals cancer cells' Achilles' heel

2013-04-24

VIDEO: The Natural Killer white blood cell in red is drawn to the cancerous B cell which has been treated with rituximab. It latches on to the side of the cell... Click here for more information. Scientists from the Manchester Collaborative Centre for Inflammation Research (MCCIR) have discovered why a particular cancer drug is so effective at killing cells. Their findings could be used to aid the design of future cancer treatments. Professor Daniel Davis and his team ...

Important fertility mechanism discovered

2013-04-24

Scientists in Mainz and Aachen have discovered a new mechanism that controls egg cell fertility and that might have future therapeutic potential. It was revealed by Professor Dr. Walter Stöcker of the Institute of Zoology at Johannes Gutenberg University Mainz (JGU) that the blood protein fetuin-B plays an important and previously unknown role in the fertilization of oocytes. Fetuin-B, first identified in the year 2000, is formed in the liver and secreted into the blood stream. During a joint research project with researchers at RWTH Aachen University headed by Professor ...

Mild blast injury causes molecular changes in brain akin to Alzheimer, Pitt team says

2013-04-24

A multicenter study led by scientists at the University of Pittsburgh School of Medicine shows that mild traumatic brain injury after blast exposure produces inflammation, oxidative stress and gene activation patterns akin to disorders of memory processing such as Alzheimer's disease. Their findings were recently reported in the online version of the Journal of Neurotrauma. Blast-induced traumatic brain injury (TBI) has become an important issue in combat casualty care, said senior investigator Patrick Kochanek, M.D., professor and vice chair of critical care medicine ...

New LED streetlight design curbs light pollution

2013-04-24

WASHINGTON, April 24, 2013—Streetlights illuminate the night, shining upon roadways and sidewalks across the world, but these ubiquitous elements of the urban environment are notoriously inefficient and major contributors to light pollution that washes out the night sky. Recent innovations in light emitting diodes (LEDs) have improved the energy efficiency of streetlights, but, until now, their glow still wastefully radiated beyond the intended area. A team of researchers from Taiwan and Mexico has developed a new lighting system design that harnesses high-efficiency LEDs ...

Recipe for low-cost, biomass-derived catalyst for hydrogen production

2013-04-24

UPTON, NY — In a paper to be published in an upcoming issue of Energy & Environmental Science (now available online), researchers at the U.S. Department of Energy's Brookhaven National Laboratory describe details of a low-cost, stable, effective catalyst that could replace costly platinum in the production of hydrogen. The catalyst, made from renewable soybeans and abundant molybdenum metal, produces hydrogen in an environmentally friendly, cost-effective manner, potentially increasing the use of this clean energy source. The research has already garnered widespread recognition ...

International study finds new genetic links to juvenile arthritis

2013-04-24

CINCINNATI – Researchers report in Nature Genetics they have increased the number of confirmed genes linked to juvenile idiopathic arthritis (JIA) from three to 17 – a finding that will clarify how JIA fits into the spectrum of autoimmune disorders and help identify potential treatment targets. Published April 21, the study involves an international research team that analyzed 2,816 JIA cases recruited from more than 40 pediatric rheumatology clinics. It was the largest collaborative patient population of JIA to date, including patient DNA samples from across the United ...

The potential oncogenic role of serum-derived hsa_circ_101555 as a non-invasive diagnostic/prognostic marker in patients with hepatocellular carcinoma

Use of traditional Chinese medicine in Chinese patients with cancer receiving outpatient care: primary reasons and communication with oncologists

[Press-News.org] Direct-acting antivirals now ready for prime time
Studies show encouraging data in a wide range of HCV patient populations

Direct-acting antivirals now ready for prime time

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: